Establishing a large prospective clinical cohort in people with head and neck cancer as a biomedical resource: head and neck 5000

BMC Cancer

Steven J Thomas⁵  Simon N Rogers^1,11  Sheila Fisher⁶  Chris Nutting⁸  Helen Worthington¹  Will Hollingworth³  Tim J Peters⁷  Susan Ring⁴  Stu Toms⁹  Christine Allmark²  Sam Leary⁹  Miranda Pring⁵  Chris Penfold⁹  Mona Jeffreys³  Katrina Hurley^1,10  Andrea Waylen⁵  Andrew Robert Ness⁹ 

[1]Cochrane Oral Health Group, School of Dentistry, University of Manchester, Manchester, UK

[2]National Cancer Research Institute Consumer Liaison Group (NCRI CLG) and Independent Cancer Patients Voice (ICPV), London, UK

[3]School of Social and Community Medicine, University of Bristol, Bristol, UK

[4]MRC Integrative Epidemiology Unit and Avon Longitudinal Study of Parents and Children, School of Social and Community Medicine, University of Bristol, Bristol, UK

[5]School of Oral and Dental Sciences, University of Bristol, Bristol, UK

[6]Leeds Institute for Cancer and Pathology, University of Leeds, Leeds, UK

[7]School of Clinical Sciences, University of Bristol, Bristol, UK

[8]Royal Marsden Hospital and the Institute for Cancer Research, London, UK

[9]National Institute for Health Research (NIHR) Biomedical Research Unit in Nutrition, Diet and Lifestyle at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol and School of Oral and Dental Sciences, University of Bristol, Bristol, UK

[10]Surgical Research Team, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

[11]Evidence-Based Practice Research Centre (EPRC), Faculty of Health and Social Care, Edge Hill University, Ormskirk, Lancashire, UK

关键词: Biological samples;    Quality of life;    Sexual history;    Patient-reported outcomes;    Prognosis research;    Clinical cohort;    Head and neck cancer;   

Others  :  1117855
DOI  :  10.1186/1471-2407-14-973

 received in 2014-11-28, accepted in 2014-12-10,  发布年份 2014

【 摘 要 】

Background

Head and neck cancer is an important cause of ill health. Survival appears to be improving but the reasons for this are unclear. They could include evolving aetiology, modifications in care, improvements in treatment or changes in lifestyle behaviour. Observational studies are required to explore survival trends and identify outcome predictors.

Methods

We are identifying people with a new diagnosis of head and neck cancer. We obtain consent that includes agreement to collect longitudinal data, store samples and record linkage. Prior to treatment we give participants three questionnaires on health and lifestyle, quality of life and sexual history. We collect blood and saliva samples, complete a clinical data capture form and request a formalin fixed tissue sample. At four and twelve months we complete further data capture forms and send participants further quality of life questionnaires.

Discussion

This large clinical cohort of people with head and neck cancer brings together clinical data, patient-reported outcomes and biological samples in a single co-ordinated resource for translational and prognostic research.

【 授权许可】

   
2014 Ness et al.; licensee BioMed Central.

【 参考文献 】

• [1]Mehanna H, Paleri V, West CML, Nutting C: Head and neck cancer-part 1: epidemiology, presentation, and prevention. Brit Med J 2010, 341:c4684.
• [2]Mehanna H, West CML, Nutting C, Paleri V: Head and neck cancer-part 2: treatment and prognostic factors. Brit Med J 2010, 341:c4690.
• [3]Drugan C, Leary S, Mellor T, Bain C, Verne J, Ness A, Thomas S: Head and neck cancer in the south west of England, Hampshire, and the Isle of Wight: trends in survival 1996–2008. Brit J Oral Max Surg 2013, 51(1):19-24.
• [4]Goulart BHL, Ramsey SD, Parvathaneni U: Observational study designs for comparative effectiveness research: an alternative approach to close evidence gaps in head-and-neck cancer. Int J Radiat Oncol 2014, 88(1):106-114.
• [5]Hemingway H, Riley RD, Altman DG: Ten steps towards improving prognosis research. Brit Med J 2009, 339:b4184.
• [6]Hemingway H, Croft P, Perel P, Hayden JA, Abrams K, Timmis A, Briggs A, Udumyan R, Moons KGM, Steyerberg EW, Roberts I, Schroter S, Altman DG, Riley RD, PROGRESS Group: Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. Brit Med J 2013, 346:e5595.
• [7]Hughes C, Homer J, Bradley P, Nutting C, Ness A, Persson M, Jeffreys M, Waylen A, Leary S, Thomas S: An evaluation of current services available for people diagnosed with head and neck cancer in the UK (2009–2010). Clin Oncol-Uk 2012, 24(10):E187-E192.
• [8]The UK National Head and Neck Audit[http://www.hscic.gov.uk/headandneck webcite]
• [9]ICD-10 Version: International Statistical Classification of Diseases and Related Health Problems 10th Revisionhttp://www.who.int/classifications/icd/en/ webcite]
• [10]Deschler D, Day T: TNM Staging of Head and Neck Cancer/Neck dissection classification. Alexandria (VA): American Academy of Head and Neck Surgery; 2008.
• [11]Adult co-morbidity evaluation-27[http://www.hscic.gov.uk/catalogue/PUB14257/clin-audi-supp-prog-head-neck-dahn-12-13-rep18.pdf webcite]
• [12]Lagiou P, Georgila C, Minaki P, Ahrens W, Pohlabeln H, Benhamou S, Bouchardy C, Slamova A, Schejbalova M, Merletti F, Richiardi L, Kjaerheim K, Agudo A, Castellsague X, Macfarlane TV, Macfarlane GJ, Talamini R, Barzan L, Canova C, Simonato L, Lowry R, Conway DI, McKinney PA, Znaor A, McCartan BE, Healy C, Nelis M, Metspalu A, Marron M, Hashibe M, Brennan PJ: Alcohol-related cancers and genetic susceptibility in Europe: the ARCAGE project: study samples and data collection. Eur J Cancer Prev 2009, 18(1):76-84.
• [13]Benzeval M, Der G, Ellaway A, Hunt K, Sweeting H, West P, Macintyre S: Cohort profile: west of scotland twenty-07 study: health in the community. Int J Epidemiol 2009, 38(5):1215-1223.
• [14]Brooks RG, Rabin F, De Charro F: The measurement and valuation of health status using EQ-5D:a European perspective:evidence from the EuroQol BIOMED Research Programme. Kluwer Academic Publishers 2003.
• [15]The Million Women Study[http://www.millionwomenstudy.org/introduction/ webcite]
• [16]The CLEAR study[http://clearstudy.org.au/about-clear-study/#.U15paflSYgg webcite]
• [17]Scheier MF, Carver CS, Bridges MW: Distinguishing optimism from neuroticism (and trait anxiety, self-mastery, and self-esteem): a reevaluation of the Life Orientation Test. J Pers Soc Psychol 1994, 67(6):1063-1078.
• [18]Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, Dehaes JCJM, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F: The European-organization-for-research-and-treatment-of-cancer Qlq-C30 - a quality-of-life instrument for use in international clinical-trials in oncology. J Natl Cancer I 1993, 85(5):365-376.
• [19]Bjordal K, Kaasa S, Ahlnerelmqvist M, Tollesson E, Bonde A: Development of a head and neck cancer-specific module for use with the Eortc core quality-of-life questionnaire (Eortc Qlq-C30). Qual Life Res 1993, 2(1):72.
• [20]Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiat Scand 1983, 67(6):361-370.
• [21]Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, Hennekens CH, Speizer FE: Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985, 122(1):51-65.
• [22]Humphris G, Ozakinci G: The AFTER intervention: a structured psychological approach to reduce fears of recurrence in patients with head and neck cancer. Br J Health Psychol 2008, 13(Pt 2):223-230.
• [23]Castellsague X, Bosch FX, Munoz N, Meijer CJLM, Shah KV, De Sanjose S, Eluf-Neto J, Ngelangel CA, Chichareon S, Smith JS, Herrero R, Moreno V, Franceschi S, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. New Engl J Med 2002, 346(15):1105-1112.
• [24]Ho KF, Farnell DJJ, Routledge JA, Burns MP, Sykes AJ, Slevin NJ, Davidson SE: Developing a CTCAEs patient questionnaire for late toxicity after head and neck radiotherapy. Eur J Cancer 2009, 45(11):1992-1998.
• [25]Hassan SJ, Weymuller EA Jr: Assessment of quality of life in head and neck cancer patients. Head Neck 1993, 15(6):485-496.
• [26]Rogers SN, Gwanne S, Lowe D, Humphris G, Yueh B, Weymuller EA Jr: The addition of mood and anxiety domains to the University of Washington quality of life scale. Head Neck 2002, 24(6):521-529.
• [27]Wright EP, Kiely M, Johnston C, Smith AB, Cull A, Selby PJ: Development and evaluation of an instrument to assess social difficulties in routine oncology practice. Qual Life Res 2005, 14(2):373-386.
• [28]Carr T, Moss T, Harris D: The DAS24: a short form of the Derriford Appearance Scale DAS59 to measure individual responses to living with problems of appearance. Br J Health Psychol 2005, 10(Pt 2):285-298.
• [29]Sandy J, Kilpatrick N, Persson M, Bessel A, Waylen A, Ness A, Ireland A: Why are multi-centre clinical observational studies still so difficult to run? Br Dent J 2011, 211(2):59-61.